12 Mar 2015
(MENAFN) Jordan’s Hikma Pharmaceuticals Plc registered USD1.49 billion revenue for the full year of 2014, marking a 9 percent increase. However, the firm forecasts a 6 percent revenue growth 2015, Reuters reported.
The Jordanian company said that 2015 revenue would be impacted by around USD45 million, or by 3 percent, that is if current exchange rates continued unchanged.
The firm’s pretax profit increased USD362 million in 2014, marking an increase from the USD298 million of 2013 due to a stronger-than-expected performance in the injectable drugs business.
“Earnings upgrades have been a key driver of outperformance over last 24 months, but a sub-par 2H14 performance coupled with a soft 2015 guidance will now break that cycle in our view,” Citi analysts said.
01 Mar 2026
BBK activates partial remote working system for its workforce to ensure employee and customer safety and service continuity
24 Feb 2026
BBK discloses its financial results for the year ended 31st December 2025
05 Feb 2026
BBK announces December Al Hayrat Grand Prize winners and another wave of Grand prizes for February
26 Jan 2026
BBK Enhances Autumn Fair 2026 Experience with Customized Rewards and Premium Services
This website uses cookies to ensure you get the best experience and by clicking “I Accept” below, you consent to the use of cookies. Learn more